source
- Cytokinetics reports Phase 3 success for Myqorzo but shares tumble as investors weigh market impactAt the European Society of Cardiology meeting, Cytokinetics presented Phase 3 data for Myqorzo in non‑obstructive hypertrophic cardiomyopathy, showing benefit in both forms of the disease and disti…
- Eli Lilly to acquire Merida Biosciences in up to $2.9 billion deal for precision antibody-degrading therapiesEli Lilly announced it will purchase Massachusetts‑based Merida Biosciences, adding a platform that can selectively degrade disease‑causing antibodies. The transaction could total up to $2.875 bil…